Erasca Q1 net loss $31M; cash $411M; IND cleared for ERAS-0015; cash runway to H2 2028

Erasca, Inc.

2025-Q1 EPS reported -$0.11

Net loss was $31.0M ($0.11/sh) vs $35.0M ($0.23/sh) in Q1 2024; R&D spend decreased to $26.0M from $28.6M.
Cash, equivalents & marketable securities $411.1M at March 31, 2025; cash runway extended to H2 2028.
IND cleared for pan-RAS molecular glue ERAS-0015; IND submitted for pan-KRAS inhibitor ERAS-4001.
Initial Phase 1 monotherapy data for both ERAS-0015 and ERAS-4001 expected in 2026.
Pursuing partnership opportunities for naporafenib to focus on RAS-targeting franchise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.